Resverlogix Corp. CEO Donald McCaffrey told BioWorld Asia he is "very confident" about collecting the potential $400 million-plus from a licensing deal in China, Hong Kong, Taiwan and Macau with Shenzhen Hepalink Pharmaceutical Co. Ltd., centered on RVX-208, a late-stage, first-in-class, small-molecule BET bromodomain inhibitor. "We downplayed the number," he said.